Navigation Links
European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
Date:6/16/2008

Worldwide COGENT-1 Study of CGT-2168 Expands to Europe; Focus on Reducing

Gastrointestinal Side Effects of Antiplatelet Therapy

MENLO PARK, Calif., June 16 /PRNewswire/ -- Cogentus Pharmaceuticals, Inc. today announced that the first patient has been enrolled in Europe in the company's pivotal Phase 3 study of its novel combination medicine CGT-2168. The patient entered the COGENT-1 study at the Zadebie cardiology clinic in Skierniewice, Poland.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071112/COGENTUSLOGO)

The study, which began in North America in January, is evaluating the antiplatelet medicine CGT-2168, a combination of clopidogrel (currently marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis as Plavix(R)) and a gastroprotectant (omeprazole) in a single pill. Developed by Cogentus, CGT-2168 is designed to provide cardiovascular benefits while reducing potentially serious gastrointestinal side effects commonly associated with dual antiplatelet therapy.

Antiplatelet therapy is an integral part of treating patients with acute coronary syndrome and has been shown to be effective in preventing major cardiovascular events. However, the combination of clopidogrel and aspirin is associated with gastrointestinal bleeding, which in some cases requires hospitalization and can even result in death.

"Millions of cardiac patients in Europe have benefited from antiplatelet therapy," said Gilles Montalescot, M.D., Ph.D., Professor of Cardiology at the Institut de Cardiologie, Pitie-Salpetriere Hospital in Paris. "It is important that our patients have access to innovative new treatment options that can enhance compliance with treatment and provide positive outcomes. We look forward to being part of the COGENT program."

Among the estimated 4,000 patients worldwide who will participate in the study, approximately half will receiv
'/>"/>

SOURCE Cogentus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. XTENT Announces European Regulatory Update
2. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
3. Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
4. European Unions CHMP Issues Positive Opinion on Sugammadex
5. PLC Systems Announces Approval of First European Study to Evaluate RenalGuard(TM)
6. PRoFESS(R) Results Announced at XVII European Stroke Conference
7. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
8. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
9. European Medicines Agency Adopts Positive Opinion for Ranolazine for Treatment of Chronic Angina
10. More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL
11. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... N.C. , Aug. 28, 2015  Delays ... research projects can slow down the decision-making process, ... is, therefore, absolutely critical for biopharmaceutical companies to ... research approval process for quicker and more meaningful ... by Best Practices, LLC, nearly three-quarters of benchmarked ...
(Date:8/28/2015)... Research and Markets ... the "12th Annual Report and Survey of ... their offering. The 2015 12th Annual ... Production is the most recent study of biotherapeutic ... future capacity and production. The report contains the ...
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/rktnl9/investigation ... "Investigation Report on China,s Insulin Aspart Market, 2010-2019" ... by Novo Nordisk, insulin aspart (under the trade ... the treatment of diabetes. Compared with human insulin, ... starts working fast and reports higher peak of ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... No Malaria Day at the Zoo to celebrate children helping children, a thank ... their congregations throughout West Ohio have contributed to the United Methodist initiative to ...
(Date:8/28/2015)... ... 28, 2015 , ... With the goal of furthering music education programs in ... the Adams County Fairgrounds in Mendon, IL on May 30th, 2015. Backed once again ... education in the underfunded school districts of Mendon and its neighboring town of Quincy, ...
(Date:8/28/2015)... ... August 28, 2015 , ... As reported by Medical Daily on August ... for results that last for two years, the longest of any cellulite reduction system ... looking for a long-lasting, effective solution for their cellulite, according to Dr. Robert Weiss, ...
(Date:8/28/2015)... ... August 28, 2015 , ... Loved ones of a person ... with chemical dependency, may be able to find some hope in the latest ... center for addiction located in Western Michigan. Focusing on several different aspects of ...
(Date:8/28/2015)... ... 2015 , ... Altima Technologies, Inc., the maker of popular ... assets and audio-video devices, recently released Visio Stencils for the following product lines: ... EMC VNX Series , Super Micro Computer SuperStorage, Hitachi Data Systems Virtual Storage ...
Breaking Medicine News(10 mins):Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3
... - Two current members step down to become ... a leading provider of wireless, handheld barcode ... that Ms. Margaret Laub, Chief Executive Officer of ... joined the IntelliDOT Board of Directors. (Logo: ...
... finisher adds large aluminum anodizing capacity to their electroplating, anodizing, and ... ... 2009 -- Team Metal Finishing announced the completion of their new ... said, "The project has been in the works for some time ...
... Whether finding will lead to treatment improvements remains unclear ... study of the effects of genetics on blood pressure ... control levels of salt in the body with high ... and stroke. , "There have been hundreds of genes ...
... 16 The Healthcare Group at Frost & Sullivan,is ... on the,European Cardiac Rhythm Management Market to be held ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ... the leading cause of premature death on a,global scale ...
... Measuring 40mm X 28mm, the new 1611RL fixed blade axial dc ... , ... Chatsworth, CA (Vocus) February 16, 2009 -- ... X 28mm fixed blade axial dc fan, specifically designed to offer ...
... NEW YORK, Feb. 15 The American Psychoanalytic Association ... their staffs for including strong privacy protections for mental ... American Recovery and Reinvestment Act of 2009. At a ... houses, jobs and health insurance has been deeply shaken ...
Cached Medicine News:Health News:Margaret Laub Appointed to IntelliDOT Board of Directors 2Health News:Margaret Laub Appointed to IntelliDOT Board of Directors 3Health News:Margaret Laub Appointed to IntelliDOT Board of Directors 4Health News:Genes That Control Body's Salt Levels Are Identified 2Health News:Genes That Control Body's Salt Levels Are Identified 3Health News:Global Economic Meltdown - Is the European Cardiac Rhythm Management Market Spared? 2Health News:Global Economic Meltdown - Is the European Cardiac Rhythm Management Market Spared? 3Health News:New Fixed Blade Axial dc Fan From NMB 2Health News:Psychoanalysts Laud Members of Congress for Inclusion of Privacy Protections in Stimulus Bill 2
Reagent Basin, 60mL, 5/Box...
Reservoir, 8 Well, 10/Box...
... manually adjustable dispensing head, and disposable, pre-sterilized ... cost-efficiency to microplate fluid dispensing. It is ... offer fast dispensing of fluids in a ... It also offers the added benefit of ...
The WellPro 384 is designed for use with 384 well microplates. It utilizes a 24 channel liquid head and can perform serial dilutions in a 16 or 24 across format, and plate to plate transfers and plat...
Medicine Products: